A leading provider of
innovative DNA Screening solutions
IGH/MAFB Translocation, Dual Fusion LPH 044
The t(14;20) translocation, present in around 2% of Multiple Myeloma cases is one of seven recurrent IGH translocations that are referred to as primary oncogenic events in Multiple Myeloma cases. These translocations result in a transcription product that dysregulates further controlling genes such as the cyclin family of cell cycle control genes which then disrupts normal cell division. As a result of the translocation the transcription of the IGH-MAFB fusion product is up-regulated which has been shown to cause overexpression of Cyclin D3 in around 7% of tumours.
IGH/MAFB Translocation, Dual Fusion
Cat. No. LPH 044-S (5 tests)
Cat. No. LPH 044 (10 tests)
- MM
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK